Novo Nordisk’s Monthly Share Plunge Largest Since Dot Com Bust | ZeroHedge
Novo Nordisk A/S shares are on track for their steepest monthly decline since the Dot-Com bust as setbacks pile up for the Danish drugmaker. Weaker-than-expected demand for Wegovy and Ozempic, disappointing mid-stage trial results for its weight-loss pill monlunabant, and poor data from another experimental shot, CagriSema, have heavily weighed on Novo share price since last June. Adding to the pressure is a broader downturn in biotech, fueled partly by Robert F. Kennedy Jr.'s (more…)